Improved corneal bioavailability of ofloxacin: Biodegradable microsphere-loaded ion-activated in situ gel delivery system

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 1427-1435

  Sayed, Elshaimaa G ^a   Hussein, Amal K ^a   Khaled, Khaled A ^a   Ahmed, Osama A A ^a,b  

^a MINIA UNIVERSITY   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Fluoroquinolones; Gellan gum; Gelrite; Orneal delivery; Simulated tear fluid

Indexed keywords

GELLAN; MICROSPHERE; OFLOXACIN; POLYGLACTIN; SOLVENT; BACTERIAL POLYSACCHARIDE; GEL; ION;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; EVAPORATION; FLOW KINETICS; GEL; IN VITRO STUDY; IN VIVO STUDY; MICROEMULSION; NONHUMAN; RABBIT; VISCOSITY; ADMINISTRATION AND DOSAGE; ANIMAL; BIOAVAILABILITY; CHEMISTRY; CORNEA; MALE; METABOLISM; PARTICLE SIZE; PHARMACOKINETICS; SURFACE PROPERTY; SYNTHESIS;

ANIMALS; BIOLOGICAL AVAILABILITY; CORNEA; DRUG DELIVERY SYSTEMS; GELS; IONS; MALE; MICROSPHERES; OFLOXACIN; PARTICLE SIZE; POLYGLACTIN 910; POLYSACCHARIDES, BACTERIAL; RABBITS; SURFACE PROPERTIES;

EID: 84928259947     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S80697     Document Type: Article

References (40)

1. Nagayama A, Nakao T, Taen H. In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis. Antimicrob Agents Chemother. 1988;32:1735–1737.
2. Chan KP, Chu KO, Lai WW, et al. Determination of ofloxacin and moxifloxacin and their penetration in human aqueous and vitreous humor by using high-performance liquid chromatography fluorescence detection. Anal Biochem. 2006;353:30–36.
3. Gwon A. Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group. Brit J Ophthalmol. 1992;76:714–718.
4. Beck R, van Keyserlingk J, Fischer U, Guthoff R, Drewelow B. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes. Graefes Arch Clin Exp Ophthalmol. 1999;237:89–92.
5. Richman J, Zolezio H, Tang-Liu D. Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms. Antimicrob Agents Chemother. 1990;34:1602–1604.
6. Sinnaeve BA, Decaestecker TN, Claerhout IJ, Kestelyn P, Remon JP, Van Bocxlaer JF. Confirmation of ofloxacin precipitation in corneal deposits by microbore liquid chromatography-quadrupole time-of-flight tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;785:193–196.
7. Järvinen K, Järvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev. 1995;16:3–19.
8. Zhang W, Prausnitz MR, Edwards A. Model of transient drug diffusion across cornea. J Control Release. 2004;99:241–258.
9. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol. 2000;27:558–562.
10. Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release. 2000;69:379–388.
11. Souza JG, Dias K, Pereira TA, Bernardi DS, Lopez RF. Topical delivery of ocular therapeutics: carrier systems and physical methods. J Pharm Pharmacol. 2014;66:507–530.
12. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57:1595–1639.
13. Hornof M, Weyenberg W, Ludwig A, Bernkop-Schnürch A. Mucoadhesive ocular insert based on thiolated poly(acrylic acid): development and in vivo evaluation in humans. J Control Release. 2003;89:419–428.
14. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release. 2007;122:119–134.
15. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev. 1995;16:61–73.
16. Radomska-Soukharev A, Wojciechowska J. Microemulsions as potential ocular drug delivery systems: phase diagrams and physical properties depending on ingredients. Acta Pol Pharm. 2005;62:465–471.
17. Carvalho EL, De la Fuente M, Seijo Rey B. [Liposomes as ocular drug delivery systems]. Arch Soc Esp Oftalmol. 2004;79:151–152. Spannish.
18. Almeida H, Amaral MH, Lobão P, Lobo JM. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today. 2014;19:400–412.
19. Järvinen T, Järvinen K. Prodrugs for improved ocular drug delivery. Adv Drug Deliv Rev. 1996;19:203–224.
20. Sultana Y, Aqil M, Ali A, Zafar S. Evaluation of carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm Dev Technol. 2006;11:313–319.
21. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm. 2009;71:445–462.
22. Sultana Y, Aqil M, Ali A, Samad A. Advances in the topical ocular drug delivery. Expert Rev Ophthalmol. 2007;2:309–323.
23. Bin Choy Y, Park JH, Prausnitz MR. Mucoadhesive Microparticles Engineered for Ophthalmic Drug Delivery. J Phys Chem Solids. 2008;69:1533–1536.
24. Patil SB, Sawant KK. Mucoadhesive microspheres: a promising tool in drug delivery. Curr Drug Deliv. 2008;5:312–318.
25. Liu Z, Li J, Nie S, Liu H, Ding P, Pan W. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm. 2006;315:12–17.
26. Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite®: A novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm. 1989;57:163–168.
27. Balasubramaniam J, Pandit JK. Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv. 2003;10:185–191.
28. Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for Indomethacin. Acta Pharm. 2003;53:251–261.
29. Sultana Y, Aqil M, Ali A. Ion-activated, Gelrite®-based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops. Drug Deliv. 2006;13:215–219.
30. El-Kamel A, Al-Dosari H, Al-Jenoobi F. Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv. 2006;13:55–59.
31. Kalam MA, Sultana Y, Samad A, et al. Gelrite-Based In Vitro Gelation Ophthalmic Drug Delivery System of Gatifloxacin. J Dispers Sci Technol. 2008;29:89–96.
32. Basci NE, Hanioglu-Kargi S, Soysal H, Bozkurt A, Kayaalp SO. Determination of ofloxacin in human aqueous humour by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal. 1997;15:663–666.
33. Kim BK, Hwang SJ, Park JB, Park HJ. Preparation and characterization of drug-loaded polymethacrylate microspheres by an emulsion solvent evaporation method. J Microencapsul. 2002;19:811–822.
34. Gavini E, Chetoni P, Cossu M, Alvarez MG, Saettone MF, Giunchedi P. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. Eur J Pharm Biopharm. 2004;57:207–212.
35. Albertsson AC, Carlfors J, Sturesson C. Preparation and characterisation of poly(adipic anhydride) microspheres for ocular drug delivery. J Appl Polym Sci. 1996;62:695–705.
36. Nafea EH, El-Massik MA, El-Khordagui LK, Marei M, Khalafallah NM. Alendronate PLGA microspheres with high loading efficiency for dental applications. J Microencapsul. 2007;24:525–538.
37. Dai L, Liu X, Tong Z. Critical behavior at sol–gel transition in gellan gum aqueous solutions with KCl and CaCl2 of different concentrations. Carbohydr Polym. 2010;81:207–212.
38. Ogawa E, Matsuzawa H, Iwahashi M. Conformational transition of gellan gum of sodium, lithium, and potassium types in aqueous solutions. Food Hydrocoll. 2002;16:1–9.
39. Rupenthal ID, Green CR, Alany RG. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release. Int J pharm. 2011;411:69–77.
40. Ravi Kumar MN. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci. 2000;3:234–258.